The Relationship between Screening Markers in the First Trimester of Pregnancy and Chromosome Aberrations

Maryam Mirsafaie, Lida Moghaddam‑ Banaem, Majid Kheirollahi


Background: This study was designed and performed to investigate the relationship between fetal chromosome aberrations and screening markers in the first trimester of pregnancy in order to prevent the birth of infants with chromosome aberrations with early prenatal diagnosis. Methods: We conducted an analytic cross‑sectional study on result of chromosomal culture of 762 pregnant women with high‑risk combined screening test from December 2018 to June 2020 and analyzed by SPSS program. Results: There was a significant relationship between chromosome structural abnormalities with free beta‑human chorionic gonadotropin (free β‑hCG) values equal to and higher than 1.5 multiples of the median (MoM) (P: 0.05). The highest incidence of disorder in number of chromosomes with abnormal nuchal translucency (NT) percentiles (≥99%) was seen (P < 0.001). It also shows that the cumulative number of chromosome aberrations of 25 (78.12%) occurred in individuals with a NT less than 99th percentile and at the same time a risk of 1/50≤ risk <1/10. Discussion: According to the results, Comparative Genomic Hybridization (CGH) array method is recommended to detect structural abnormalities in chromosomes in samples with NT ≥3.5. In addition, it is noteworthy that chromosomal structural abnormalities occur in free β‑hCG ≥1.5 MoM. Conclusion: Due to the frequency of chromosomal structural disorders and its effect on the incidence of fetal abnormalities, the study of chromosomal structural disorders is recommended.


Chromosome aberrations; first trimester pregnancy; human chorionic gonadotropin beta subunit; pregnancy‑associated plasma protein‑A; nuchal translucency

Full Text:



Kirkegaard I, Henriksen T, Uldbjerg N. Early fetal growth,

PAPP‑A and free β‑hCG in relation to risk of delivering a

small‑for‑gestational age infant. Ultrasound Obstet Gynecol


Shiefa S, Amargandhi M, Bhupendra J, Moulali S, Kristine T.

First trimester maternal serum screening using biochemical

markers PAPP‑A and free β‑hCG for down syndrome, patau

syndrome and edward syndrome. Indian J Clin Biochem


Bilancia CG, Ganapathi M, Levy B. 24‑Prenatal diagnosis of

chromosome abnormalities. In: Pandya PP, Oepkes D, Sebire NJ,

Wapner RJ, editors. Fetal Medicine (Third Edition). London:

Elsevier; 2020. p. 233‑46.e3.

Khandekar S, Dive A, Munde P. Chromosomal abnormalities‑a

review. Central India J Dent Sci. 2013;4:35‑40.

Ziolkowska K, Dydowicz P, Sobkowski M, Tobola‑Wrobel K,

Wysocka E, Pietryga M. The clinical usefulness of

biochemical (free β‑hCG, PAPP‑A) and ultrasound (nuchal

translucency) parameters in prenatal screening of trisomy 21 in

the first trimester of pregnancy. Ginekol Pol 2019;90:161‑6.

Rink BD, Norton ME, Screening for fetal aneuploidy. Semin

Perinatol. 2016;40:35-43. doi: 10.1053/j.semperi.2015.11.006.

Epub 2015 Dec 25.

Benn P, Borrell A, Crossley J, Cuckle H, Dugoff L, Gross S et

al., Aneuploidy screening: a position statement from a committee

on behalfof the Board of the International Society for Prenatal

Diagnosis, January 2011. Prenat Diagn 2011;31:519-22.

Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr‑Urtreger A.

Decreased first trimester PAPP‑A is a predictor of adverse

pregnancy outcome. Prenat Diagn 2002;22:778‑82.

Patil M, Panchanadikar T, Wagh G. Variation of papp‑a level in

the first trimester of pregnancy and its clinical outcome. J Obstet

Gynecol India 2014;64:116‑9.

Hsu J, Ou Y, Chen K, Hsieh T, Soong Y. High maternal

serum free beta‑hCG levels in Down syndrome pregnancies:

A preliminary report. Changgeng Yi Xue Za Zhi.


Yaron Y, Ochshorn Y, Tsabari S, Shira AB. First‑trimester nuchal

translucency and maternal serum free β‑hCG and PAPP‑A can

detect triploidy and determine the parental origin. Prenat Diagn


Grande M, Jansen F, Blumenfeld Y, Fisher A, Odibo A, Haak M,

et al. Genomic microarray in fetuses with increased nuchal

translucency and normal karyotype: A systematic review and

meta‑analysis. Ultrasound Obstet Gynecol 2015;46:650‑8.

Sadłecki P, Walentowicz‑Sadłecka M, Pasińska M, Adamczak R,

Grabiec M. Indications for genetic amniocentesis investigated

at the Department of Gynecology, Obstetrics, and Oncologic

Gynecology, Nicolaus Copernicus University, Collegium

Medicum, Bydgoszcz. Ginekol Pol 2014;85:420.